Sorry, there was a problem.

An unexpected error occurred and your request couldn't be handled. Please call a Dignity Health representative at
(844) 274-8497
OR
Chat with us here.

Reference code:

Pulmonary, Infectious Disease and Critical Care Symposium


Empiric Therapy and Recent Advances         

Thank you for your interest in Mercy General Hospital's 38th Annual Pulmonary, Infectious Disease, and Critical Care Symposium: a special two-day CME opportunity presenting the latest information on current and upcoming treatments and research. 

Event Details 

Friday & Saturday, September 14-15, 2018

California Northstate University, Event Center

9650 W Taron Dr.

Elk Grove, CA 95757

 

ONLINE REGISTRATION NOW OPEN BELOW. 

 

7:30 a.m. Registration, breakfast, and networking     

8:00 a.m. Welcome    

4:30 p.m. Closing Remarks/Adjourn

 

Our featured presentations will include:

Friday, September 14, 2018

Fluid Resuscitation in Circulatory Shock: Current Concepts
Nazir J. Habib, MD
Targeted Temperature Management: Is It Cool? 
Lara Zimmermann, MD
Updates on Interventional Pulmonary Medicine
Shawn Aghili, MD
What Causes Autoimmune Disease: Primary Biliary Cholangitis - Paradigm or Paradox?  
M. Eric Gershwin, MD
Hyponatremia Management  
Nazir J. Habib, MD
Overview of Pulmonary Hypertension for Practitioners on the Frontline 
Roblee P. Allen, MD
The Basis of Gender Biased Autoimmunity: Why Do Women Get More Autoimmune Diseases?  
M. Eric Gershwin, MD
Dementia And Delirium: Connect The Dots?  
Nazir J. Habib, MD


Saturday, September 15, 2018

Pharmacokinetic and Pharmacodynamic Principles of Antibacterial Agents  
Charles A. Peloquin, PharmD
C-Diff: Can We Do Better?
Stuart Cohen, MD
Sepsis: Empiric and Documented Management
Henry Chambers, MD
Short Course Antibiotic Therapy  
Brad Spellberg, MD
Rapid Diagnostics for Clinicians 
Henry Chambers, MD
Mycobacterial Infections: Is There A Cure?  
Stuart Cohen, MD
Antibiotic Stewardship for the 21st Century    
Brad Spellberg, MD
Incidence of Tuberculous With Implications for Anti-Tb Chemotherapy   
Charles A. Peloquin, PharmD


Objectives:

At the conclusion of our program, participants should be able to implement the following changes to their professional practice:

  • Evaluate optimum fluid type and volume to recognize and reduce complications of fluid resuscitation. 
  • Describe implementation and appropriateness of targeted temperature management following acute brain injury and cardiac arrest.
  • Recognize indications for pulmonary interventions and benefits of new procedures for benign and malignant lung diseases.
  • Summarize pathophysiology and prevention of Primary Biliary Cholangitis. 
  • Diagnose types of hyponatremia on presentation in order to manage and monitor complications.
  • Recognize the pathophysiology, diagnosis, and implications for treatment of pulmonary hypertension.
  • Summarize why women get more autoimmune diseases.
  • Define strategies for early diagnosis and management of dementia and delirium for better outcomes. 
  • Identify pharmacokinetic and pharmacodynamics of antibiotic agents, and apply to clinical practice. 
  • Apply strategies for diagnosis, management, and prevention of Clostridium difficile infection.
  • Assess patient risk and select antibiotic and adjunctive therapy in treatment of sepsis. 
  • Prescribe shorter antibiotic courses to enable better outcomes.
  • Utilize rapid diagnostic test results to improve medical management. 
  • Diagnose nontuberculous mycobacteria infections and optimize treatment. 
  • Improve patient care through antibiotic stewardship.
  • Assess new pharmacological treatment options for patients with tuberculosis. 

Disclosures:

As a provider accredited by the Institute for Medical Quality/California Medical Association, we must ensure balance, independence, objectivity and scientific rigor in all of our sponsored educational activities. We at Dignity Health Sacramento Office of Continuing Medical Education adhere to the ACCME Standards for Commercial Support.

The following speakers have indicated an affiliation with organizations which have interests related to the content of this program. Per Dignity Health Sacramento CME office policy, these potential conflicts of interest have been resolved.

  • Dr. Cohen serves as a principal investigator for Pfizer, Rebiotix, Seres, and Merck
  • Dr. Spellberg receives fees as a consultant for Nabriva, Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, and Ovagene, equity shareholder for Motif, BioAIM, Synthetic Biologics, and Mycomed
  • Dr. Habib receives fees as a speaker and consultant for the Speakers Bureau 
  • Dr. Murphy receive fees as a speaker for La Jolla Pharmaceuticals 
  • Dr. Wong serves as Chairman of the Board for Vortran Medical 

The potential conflicts of interest have been resolved and determined the presentations are without bias.

  • Drs. Allen, Zimmermann, Aghili, Gershwin, Peloquin, Chambers, DeFelice, and Yu the Dignity Health Sacramento CME committee members, and all other planners’ involved and able to influence the content of this presentation, have reported no relevant financial relationships/interest with any commercial entities that may have ties to this presentation.


This educational activity is supported in part by educational grants.


Accreditation Statement:

Dignity Health Sacramento is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. 

Credit Designation:

Dignity Health Sacramento designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 CME IMQ Logo